Neurocrine Biosciences, Inc. (LON:0K6R)
London · Delayed Price · Currency is GBP · Price in USD 125.14
-11.32 (-8.29%)
Feb 12, 2026, 4:55 PM GMT
Neurocrine Biosciences Market Cap
Neurocrine Biosciences has a market cap or net worth of 10.04 billion as of February 12, 2026. Its market cap has decreased by -18.14% in one year.
Market Cap
10.04B
Enterprise Value
9.26B
Revenue
2.13B
Ranking
n/a
PE Ratio
28.24
Stock Price
125.14
Market Cap Chart
Since May 23, 1996, Neurocrine Biosciences's market cap has increased from 136.97M to 10.04B, an increase of 7,232.81%. That is a compound annual growth rate of 15.54%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 11, 2026 | 10.04B | -4.41% |
| Dec 31, 2025 | 10.51B | -4.82% |
| Dec 31, 2024 | 11.04B | 8.62% |
| Dec 29, 2023 | 10.16B | 6.65% |
| Dec 30, 2022 | 9.53B | 59.70% |
| Dec 31, 2021 | 5.97B | -9.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 215.40B |
| GSK plc | 86.64B |
| Haleon | 34.95B |
| Smith & Nephew | 10.82B |
| Convatec Group | 4.41B |
| Hikma Pharmaceuticals | 3.39B |
| Genus | 2.04B |
| HUTCHMED (China) | 1.82B |